Nexpoint Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Nexpoint Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.5M	Buy	+2,039,280	New	+$29.2M	1.98%	18
2021 Q3	–	Sell	-56,617	Closed	-$546K	–	182
2021 Q2	$546K	Hold	56,617	–	–	0.12%	88
2021 Q1	$559K	Sell	56,617 -633	-1%	-$9.8K	0.15%	84
2020 Q4	$1.32M	Hold	57,250	–	–	0.43%	58
2020 Q3	$808K	Sell	57,250 -8,450	-13%	-$123K	0.18%	87
2020 Q2	$991K	Hold	65,700	–	–	0.22%	74
2020 Q1	$607K	Hold	65,700	–	–	0.11%	113
2019 Q4	$640K	Hold	65,700	–	–	0.05%	175
2019 Q3	$527K	Buy	+65,700	New	+$713K	0.03%	244

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Nexpoint Asset Management's FOLD Position: Q1 2026 in Review

Nexpoint Asset Management opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 2,039,280 shares worth $29.5M. The stake represents 1.98% of the portfolio and ranks #18 among its holdings. This is a return to the name: Nexpoint Asset Management previously reported a position in FOLD as recently as Q2 2021.

Nexpoint Asset Management first reported a position in FOLD in Q3 2019 and has held it in 9 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Nexpoint Asset Management held 2,039,280 shares of Amicus Therapeutics worth $29.5M as of Q1 2026.
Amicus Therapeutics was a new Nexpoint Asset Management position in Q1 2026.
Amicus Therapeutics made up 1.98% of Nexpoint Asset Management's portfolio in Q1 2026, its #18 holding.
Nexpoint Asset Management first reported a position in Amicus Therapeutics in Q3 2019 and has held it in 9 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Nexpoint Asset Management's 13F filing for Q1 2026, filed 15 May 2026.